Novo Nordisk A/S is a Danish multinational pharmaceutical firm headquartered in Bagsværd, with manufacturing facilities across nine countries and affiliates or offices in five others. The company is predominantly controlled by its majority shareholder, Novo Holdings A/S, which owns approximately 28.1% of its shares and a majority of its voting rights.

Novo Nordisk specializes in the production and marketing of pharmaceutical products and services, focusing primarily on diabetes care medications and devices. Among its key products is semaglutide, utilized for diabetes treatment under the brand names Ozempic and Rybelsus, as well as for obesity treatment under the brand name Wegovy. The company also engages in hemostasis management, growth hormone therapy, and hormone replacement therapy, producing numerous drugs under various brand names such as Levemir, Tresiba, NovoLog, Novolin R, NovoSeven, NovoEight, and Victoza.

Employing over 48,000 individuals worldwide, Novo Nordisk distributes its products in 168 countries. The corporation was formed in 1989 from a merger of two Danish companies with origins tracing back to the 1920s. The Novo Nordisk logo features the Apis bull, a sacred animal from ancient Egypt, represented by the hieroglyph 𓃒. Novo Nordisk is also a full member of the European Federation of Pharmaceutical Industries and Associations.

Recognized for its workplace culture, the company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, later ranking 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was acclaimed as the most sustainable company globally by Corporate Knights, while its spin-off, Novozymes, secured the fourth position. The company is a leader in the FTSE4Good Index and stands as the only European firm in the top ten list. As the largest pharmaceutical company in Denmark, Novo Nordisk's market capitalization surpassed the GDP of Denmark's domestic economy in 2023, making it the highest valued company in Europe, with net sales reaching US$42.121 billion in 2024.

Novo Nordisk A/S Profile



Ticker SymbolNVO

Company nameNovo Nordisk A/S

IPO dateMay 17, 1974

CEODoustdar (Maziar Mike)

Number of employees76302

Security typeDepository Receipt

Fiscal year-endMay 17

AddressNovo Alle 1

CityBAGSVAERD

Stock exchangeNASDAQ OMX NASDAQ Basic NYSE

CountryDenmark

Postal code2880

Phone4544448888

Websitehttps://www.novonordisk.com/

Ticker SymbolNVO

IPO dateMay 17, 1974

CEODoustdar (Maziar Mike)

Company Executives of Novo Nordisk A/S



Name

Name/Position

Position

Shareholding

Change

Mr. Emil Kongshoj Larsen

Executive Vice President - International Operations

Dr. Cees de Jong

Independent Vice Chairman of the Board

Mr. Stephan Engels

Independent Director

Ms. Britt Meelby Jensen

Director

Mr. Kasper Bodker Mejlvang

Executive Vice President - Chemistry, Manufacturing and Control (CMC) and Product Supply

Ms. Elin Jager

Senior Vice President, Chief of Staff to CEO; Corporate Strategy and Sustainability

Mr. John F. Kuckelman

Senior Vice President, Group General Counsel, Global Legal, IP and Security

Ms. Semsi Kilic Madsen

Director, Employee Representative

Ms. Desiree Jantzen Asgreen

Director, Employee Representative

Ms. Helena Saxon

Independent Director

Name

Name/Position

Position

Shareholding

Change

Mr. Emil Kongshoj Larsen

Executive Vice President - International Operations

Dr. Cees de Jong

Independent Vice Chairman of the Board

Mr. Stephan Engels

Independent Director

Ms. Britt Meelby Jensen

Director

Mr. Kasper Bodker Mejlvang

Executive Vice President - Chemistry, Manufacturing and Control (CMC) and Product Supply

Ms. Elin Jager

Senior Vice President, Chief of Staff to CEO; Corporate Strategy and Sustainability

FAQs

Who are the top five shareholders of Novo Nordisk A/S?



The top five shareholders of Novo Nordisk A/S are: Mr. Emil Kongshoj Larsen

How many institutions hold shares of Novo Nordisk A/S (NVO)?



As of 2026Q1, 2975 institutions hold shares of Novo Nordisk A/S, with a combined market value of approximately 332.82M, accounting for 9.89% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -2714627.00.

What is the biggest source of revenue for Novo Nordisk A/S?



In 2026Q1, the Total GLP-1 business generated the highest revenue for Novo Nordisk A/S, amounting to 5.72B and accounting for 46.87% of total revenue.